SANTA CLARA, Calif.,
May 2, 2011 /PRNewswire/ --
NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology
provider, today announced its selection for the prestigious NYC
Bright Lights Conference at the Le Parker Meridien Hotel in New
York City. Bright Lights is the only conference of its kind
with an exclusive focus on publicly traded companies with
disruptive and market changing intellectual property (IP).
NewCardio will present on May 10,
2011 at 9 a.m. ET.
NewCardio was selected from MDB's 2011 group of "Best and
Brightest" small-cap companies, a group that is advancing some of
today's most innovative and market-leading intellectual property
(IP). It is one of the 40 public companies ranking in the 90th
percentile for its respective technology leadership from more than
1,500 small-cap companies with granted U.S. patents, as rated by
PatentVest, MDB's proprietary IP business intelligence
platform.
Christopher Marlett, CEO at MDB
Capital Group, comments, "It's a rare and exciting opportunity to
have so many key players that are driving IP asset monetization
together under one roof and we look forward to sharing NewCardio's
cardiac diagnostic technology with other innovators and investors
at the Bright Lights conference."
Bright Lights also features high-profile speakers including the
top IP experts in the nation, such as David
Kappos, Under Secretary of Commerce for Intellectual
Property and Director of the United States Patent and Trademark
Office (USPTO), who will be joining as a keynote speaker; in
addition to Marshall Phelps, former
head of Microsoft IP, and John
Cronin, former head of IBM's Patent Factory, and
Paul Ryan of Acacia Research.
The second annual Bright Lights Conference will take place on
May 10 - 11th at the Le Parker
Meridien Hotel in New York City. To learn more about the
event, please visit: http://www.mdb.com.
Investors and other interested parties may access an audio only
webcast of the live presentation at
http://www.wsw.com/webcast/mdb2/nwci.ob/. This webcast will be
archived for 90 days following the live presentation.
About MDB Capital Group
MDB Capital Group, LLC is an institutional research and
investment banking firm focusing exclusively on small and micro-cap
companies possessing market changing, disruptive intellectual
property. For more information on MDB Capital Group, visit:
http://www.mdb.com
About PatentVest
PatenVest® is a proprietary intellectual property (IP) business
intelligence platform developed by MDB Capital Group. PatentVest
quantifies the appropriate valuation of IP and enables the
emergence of IP as an investible asset class. For more information
on PatentVest please visit: http://www.patentvest.com
DISCLAIMER
Past performance is not a guarantee of future results. MDB
Capital Group, LLC expects to receive or intends to seek
compensation for investment banking or other business relationships
with the covered companies mentioned in this press release. For
important disclosure information regarding the covered companies in
this press release, please contact: The Director of Research at
(310) 526-5000 or write to: MDB Capital Group, LLC, Attention:
Director of Research, 401 Wilshire Blvd., Suite 1020, Santa Monica, CA 90401.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company
developing and marketing proprietary software platform technologies
to provide higher accuracy to, and increase the value of, the
standard 12L ECG. NewCardio's 3-D ECG software platform reduces the
time and expense involved in assessing cardiac status while
increasing the ability to diagnose clinically significant
conditions which were previously difficult to detect. NewCardio's
software products and services significantly improve the diagnosis
and monitoring of cardiovascular disease, as well as cardiac safety
assessment of drugs under development. For more information, visit
www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include, but are not limited to,
statements that express our intentions, beliefs, expectations,
strategies, predictions or any other statements relating to our
future activities or other future events or conditions. These
statements are based on current expectations, estimates and
projections about our business based on currently available
information and assumptions made by management. Although we believe
that the assumptions on which the forward-looking statements
contained herein are based are reasonable, any of those assumptions
could prove to be inaccurate given the inherent uncertainties as to
the occurrence or nonoccurrence of future events. These statements
are not guarantees of future performance and involve risks and
uncertainties that are difficult to predict. Therefore, actual
outcomes and results may, and are likely to, differ materially from
what is expressed or forecasted in the forward-looking statements
due to numerous factors, including the potential risks and
uncertainties set forth in Item 1A of our Annual Report on Form
10-K for the year ended December 31,
2010 and relate to our business plan, our business strategy,
development of our proprietary technology platform and our
products, timing of such development, timing and results of
clinical trials, level and timing of FDA regulatory clearance or
review, market acceptance of our products, protection of our
intellectual property, implementation of our strategic, operating
and people initiatives, benefits to be derived from personnel and
directors, ability to commercialize our products, our assumptions
regarding cash flow from operations and cash on-hand, the amount
and timing of operating costs and capital expenditures relating to
the expansion of our business, operations and infrastructure,
implementation of marketing programs, our key agreements and
strategic alliances, our ability to obtain additional capital as,
and when, needed, and on acceptable terms and general economic
conditions specific to our industry, any of which could impact
sales, costs and expenses and/or planned strategies and timing. We
assume no obligation to, and do not currently intend to, update
these forward-looking statements.
To join our email distribution please click this link:
http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio, Inc.